LRMR
LRMR clinical trials: Larimar Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Larimar Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 8
- Trials linked
- 8
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
LRMR on the catalyst calendar · LRMR registry changes
- Primary completion Jul 2029Sponsor estimatePhase 3NCT07778836A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's AtaxiaLarimar Therapeutics, Inc. · Friedreich AtaxiaRecruitingLRMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2027Sponsor estimatePhase 2NCT06447025An Open-Label Study of CTI-1601 in Subjects With Friedreich's AtaxiaLarimar Therapeutics, Inc. · Friedreich AtaxiaRecruitingLRMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 27, 2025ActualPhase 1NCT06681766A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's AtaxiaLarimar Therapeutics, Inc. · Friedreich AtaxiaTerminatedLRMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 4, 2023ActualPhase 2NCT05579691A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's AtaxiaLarimar Therapeutics, Inc. · Friedreich AtaxiaCompletedLRMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 4, 2022ActualNo phase registeredNCT05028764Determine Range of Tissue Frataxin Concentrations and Other Potential BiomarkersLarimar Therapeutics, Inc. · Friedreich AtaxiaCompletedLRMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 16, 2021ActualPhase 1NCT04519567Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaLarimar Therapeutics, Inc. · Friedreich AtaxiaCompletedLRMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 31, 2020ActualPhase 1NCT04176991Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaLarimar Therapeutics, Inc. · Friedreich AtaxiaCompletedLRMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 30, 2020ActualNo phase registeredNCT04255680A Study to Assess Variation in Potential Biomarkers in Friedreich AtaxiaLarimar Therapeutics, Inc. · Friedreich AtaxiaCompletedLRMRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 8 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner